IRIDEX Corporation (IRIX)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $12.08M
Last updated: Nov 17, 2026 at 4:42 PM ET
IRIDEX Corporation (IRIX) Statistics
IRIDEX (IRIX) has a market cap of $12.08M and an enterprise value of $11.34M. Its share count is up 3.47% from a year earlier.
Total Valuation
Enterprise value is 6.16% below the market cap, as cash exceeds debt.
| Market Cap | $12.08M |
|---|---|
| Enterprise Value | $11.34M |
| Latest price (Nov 17, 2026) | $0.70 |
Key Dates
The next earnings report is set for Nov 17, 2026, after the close.
| Next Earnings Date | Nov 17, 2026, after the close |
|---|---|
| Last Earnings Date | Aug 18, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.2x and 3.3x. Its year-end P/S ranged from 0.4x to 3.1x from 2016 to 2025.
| P/S Ratio | 0.2x |
|---|---|
| Forward P/S | 0.2x |
| P/B Ratio | 3.3x |
| P/TBV Ratio | 6.6x |
Enterprise Valuation
Counting debt and cash, the company is valued at 110.8x EBITDA.
| EV / Sales | 0.2x |
|---|---|
| EV / EBITDA | 110.8x |
Price Statistics
The stock is down 28.61% over 52 weeks and trades 1.41% below its 50-day average.
| Beta (1Y) | 0.85 |
|---|---|
| 52-Week Change | -28.61% |
| 1-Month Change | -9.14% |
| 3-Month Change | -10.64% |
| 6-Month Change | -33.37% |
| 5-Year Change | -90.72% |
| 10-Year Change | -94.75% |
| Total Return (1Y) | -28.61% |
| Total Return (3Y CAGR) | -29.30% |
| Total Return (5Y CAGR) | -37.65% |
| Max Drawdown (1Y) | -61.09% |
| Max Drawdown (3Y) | -82.80% |
| Sharpe Ratio (1Y) | -0.41 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $0.71 |
| 200-Day Average | $0.99 |
| 52-Week Range | $0.61 to $1.65 |
| RSI (14 Days) | 47.2 |
| Average Volume (20 Days) | 32.52K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.82x current liabilities, and total debt is 1.08x shareholder equity.
| Current Ratio | 1.82x |
|---|---|
| Quick Ratio | 1.08x |
| Debt / Equity | 1.08x |
| Debt / EBITDA | 38.21x |
| Interest Coverage | -2.30x |
Returns and Efficiency
Return on invested capital is -18.73% over the last 12 months, against a 5-year average of -64.94%.
| Return on Equity (ROE) | -97.47% |
|---|---|
| Return on Assets (ROA) | -13.01% |
| Return on Invested Capital (ROIC) | -18.73% |
| Return on Capital Employed (ROCE) | -10.07% |
| ROA (5Y Average) | -20.43% |
| ROIC (5Y Average) | -64.94% |
| Asset Turnover | 1.75x |
| Inventory Turnover | 3.45x |
| Receivables Turnover | 6.65x |
| Cash Conversion Cycle | 92 days |
Scores
IRIX has an Altman Z-Score of -2.34, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -2.34 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $51.57M over the last 12 months is up 3.68% from the 12 months before.
| Revenue | $51.57M |
|---|---|
| Revenue Growth (YoY) | +3.68% |
| Gross Profit | $18.68M |
| Operating Income | -$2.78M |
| Pretax Income | -$3.40M |
| Net Income | -$3.55M |
| EBITDA | $103.00K |
| EBIT | -$1.42M |
| Reported EPS (TTM) | -$0.20 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 13.35% of the $27.26M in total assets.
| Cash and Equivalents | $4.68M |
|---|---|
| Total Debt | $3.94M |
| Net Cash | $744.00K |
| Net Cash Per Share | $0.04 |
| Working Capital | $10.79M |
| Shareholder Equity | $3.64M |
| Book Value Per Share | $0.21 |
| Tangible Book Value | $1.85M |
| Tangible Book Per Share | $0.11 |
| Total Assets | $27.26M |
| Total Liabilities | $23.62M |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $270.00K of capital spending, operating cash flow left -$2.00M of free cash flow.
| Operating Cash Flow | -$1.73M |
|---|---|
| Capital Expenditures | $270.00K |
| Free Cash Flow | -$2.00M |
| FCF Per Share | -$0.11 |
| Depreciation and Amortization | $1.52M |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is -5.39%, against a 5-year average of -13.69%.
| Gross Margin | 36.23% |
|---|---|
| Operating Margin | -5.39% |
| Pretax Margin | -6.58% |
| Net Margin | -6.88% |
| EBITDA Margin | 0.20% |
| EBIT Margin | -2.75% |
| FCF Margin | -3.88% |
| Gross Margin (5Y Average) | 41.13% |
| Operating Margin (5Y Average) | -13.69% |
| Net Margin (5Y Average) | -13.62% |
Growth
Revenue fell 2.58% a year over 3 years.
| Revenue Growth (3Y CAGR) | -2.58% |
|---|---|
| Revenue Growth (5Y CAGR) | +7.70% |
| Book Value Per Share Growth (2Y CAGR) | -30.10% |
| Tangible Book Per Share Growth (2Y CAGR) | -36.25% |
Dividends and Yields
IRIX does not pay a dividend. Its free cash flow yield is -16.45%.
| FCF Yield | -16.45% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 10 similar companies, IRIX has the lowest P/S and the 2nd highest ROIC.
P/S RatioPeer median 1.6x
ROICPeer median -155.44%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +31.52%
| P/S Ratio | 0.2x vs 1.6x median |
|---|---|
| ROIC | -18.73% vs -155.44% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +3.68% vs +31.52% median |
Analyst Forecast
Consensus estimates put revenue growth at 3.09% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +3.09% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About IRIX
What is IRIX's market cap?
IRIDEX has a market cap of $12.08M. Its enterprise value, which adds debt and subtracts cash, is $11.34M.
How many shares of IRIX are outstanding?
IRIDEX has 17.38M shares outstanding. The count is up 3.47% from a year earlier.
Does IRIX pay a dividend?
No. IRIDEX does not pay a dividend.
How much debt does IRIX have?
IRIDEX has $3.94M of total debt and $4.68M of cash and equivalents, a net cash position of $744.00K.
IRIX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts